Overview

Study of VX-770 on Desipramine

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the effects of VX-770 on Desipramine
Phase:
Phase 1
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Treatments:
Desipramine
Ivacaftor